Insulin, Hyperglycemia, and Severe Retinopathy of Prematurity in Extremely Low-Birth-Weight Infants

Página do item simplificado
dc.citation.issue4
dc.citation.volume33
dc.contributor.authorLee, Jan Hau
dc.contributor.authorHornik, Christoph P.
dc.contributor.authorTestoni, Daniela [UNIFESP]
dc.contributor.authorLaughon, Matthew M.
dc.contributor.authorCotten, C. Michael
dc.contributor.authorMaldonado, Ramiro S.
dc.contributor.authorBelcastro, Marc R.
dc.contributor.authorClark, Reese H.
dc.contributor.authorSmith, P. Brian
dc.coverageNew York
dc.date.accessioned2020-08-21T17:00:08Z
dc.date.available2020-08-21T17:00:08Z
dc.date.issued2016
dc.description.abstractObjective This study aims to determine the association between hyperglycemia, insulin therapy, and severe retinopathy of prematurity (ROP) in extremely low-birth-weight (ELBW) infants. Study Design In this retrospective database study, we included all ELBW infants who were <= 32 weeks gestational age (GA). We excluded infants without any ophthalmology evaluation and infants who died before 28 days of life. A multivariable model was constructed to determine the association between hyperglycemia, insulin use, and severe ROP. We defined hyperglycemia as blood glucose (BG) > 180 mg/dL. Covariates were GA, small for GA status, discharge year, sex, Apgar score at 5 minutes, mechanical ventilation, oxygen use, bacteremia, and postnatal steroid exposure. We defined severe ROP as ROP requiring bevacizumab, cryotherapy, laser therapy, or vitrectomy. Sensitivity analysis using BG > 150 mg/dL and > 200 mg/dL was performed. Results A total of 24,548 infants were included; 2,547 (10%) had severe ROP. Hyperglycemia alone was not associated with severe ROP (odds ratio [OR], 0.88; 95% confidence interval [CI], 0.66-1.17). Hyperglycemia and insulin use were not associated with severe ROP (OR, 1.43; 95% CI, 0.91-2.23). BG > 150 mg/dL and insulin use were associated with severe ROP (OR, 1.34; 95% CI, 1.02-1.76). Conclusions Hyperglycemia alone was not associated with severe ROP in ELBW infants. However, we did observe a possible trend between the use of insulin and severe ROP.en
dc.description.affiliationDuke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USA
dc.description.affiliationDuke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA
dc.description.affiliationKK Womens & Childrens Hosp, Childrens Intens Care Unit, Singapore, Singapore
dc.description.affiliationUniv Fed Sao Paulo, Ecola Paulista Med, Div Neonatal Med, Sao Paulo, Brazil
dc.description.affiliationUniv N Carolina, Dept Pediat, Chapel Hill, NC USA
dc.description.affiliationMEDNAX Inc, Pediat Med Grp, Jacksonville, FL USA
dc.description.affiliationUnifespUniv Fed Sao Paulo, Ecola Paulista Med, Div Neonatal Med, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipNational Center for Advancing Translational Sciences of the National Institutes of Health (NIH)
dc.description.sponsorshipU.S. government
dc.description.sponsorshipNational Institute of Child Health and Human Development
dc.description.sponsorshipNIH
dc.description.sponsorshipNational Center for Advancing Translational Sciences of the NIH
dc.description.sponsorshipU.S. Food and Drug Administration
dc.description.sponsorshipCempra Pharmaceuticals
dc.description.sponsorshipIDNIH: UL1TR001117
dc.description.sponsorshipIDU.S. government: HHSN267200700051C
dc.description.sponsorshipIDNational Institute of Child Health and Human Development: K23HD068497
dc.description.sponsorshipIDNational Institute of Child Health and Human Development: HHSN275201000003I
dc.description.sponsorshipIDNational Institute of Child Health and Human Development: 1R01-HD081044-01
dc.description.sponsorshipIDNational Center for Advancing Translational Sciences of the NIH: UL1TR001117
dc.description.sponsorshipIDU.S. Food and Drug Administration: 1R18-FD005292-01
dc.description.sponsorshipIDCempra Pharmaceuticals: HHS0100201300009C
dc.format.extent393-400
dc.identifierhttp://dx.doi.org/10.1055/s-0035-1565999
dc.identifier.citationAmerican Journal Of Perinatology. New York, v. 33, n. 4, p. 393-400, 2016.
dc.identifier.doi10.1055/s-0035-1565999
dc.identifier.fileWOS000372062200010.pdf
dc.identifier.issn0735-1631
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/57882
dc.identifier.wosWOS:000372062200010
dc.language.isoeng
dc.publisherThieme Medical Publ Inc
dc.relation.ispartofAmerican Journal Of Perinatology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjecthyperglycemiaen
dc.subjectretinopathy of prematurityen
dc.subjectextremely low birth weighten
dc.subjectinfantsen
dc.titleInsulin, Hyperglycemia, and Severe Retinopathy of Prematurity in Extremely Low-Birth-Weight Infantsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000372062200010.pdf
Tamanho:
343.04 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos